NOVELTY - Substantially pure crystalline form I of apixaban having e.g. (a) X-ray powder diffraction pattern comprising peak at 16.98 degrees in term of 2 theta , (b) X-ray powder diffraction pattern comprising peaks at 16.98, 18.44, 26.98, 13.92 and 22.11 degrees in term of 2 theta , (c) X-ray powder diffraction pattern comprising at least one peak at 16.98, 18.44, 26.98, 13.92, 22.11,21.12, 12.84, 22.26 and 21.56 degrees , (d) an X-ray powder diffraction pattern comprising at least one peak at 16.98, 18.44, 26.98, 13.92, 22.11, 21.12, 12.84, 22.26, 21.56, 24.75, 18.81, 19.57, 29.93, 28.69 and 16.24 degrees is new.    USE - The crystalline and amorphous forms of apixaban are useful for preventing or treating a thromboembolic disorder (claimed). No biological data given.    ADVANTAGE - The crystalline and amorphous forms of apixaban: exhibit high chemical purity, high flowability, high solubility, high morphology or high crystal habit, stability (storage stability and stability to polymorphic conversion), low hygroscopicity and has low content of residual solvents; and are prepared at high yields and high purity by the process that complies with factory good manufacturing practice production requirements and is environmentally friendly.    DETAILED DESCRIPTION - Substantially pure crystalline form I of apixaban having (a) an X-ray powder diffraction pattern comprising a peak at 16.98 degrees in term of 2 theta , (b) an X-ray powder diffraction pattern comprising at least one peaks at 16.98, 18.44, 26.98, 13.92 and 22.11 degrees in term of 2 theta , (c) an X-ray powder diffraction pattern comprising at least one peak at 16.98, 18.44, 26.98, 13.92, 22.11,21.12, 12.84, 22.26 and 21.56 degrees in term of 2 theta , (d) an X-ray powder diffraction pattern comprising at least one peak at 16.98, 18.44, 26.98, 13.92, 22.11, 21.12, 12.84, 22.26, 21.56, 24.75, 18.81, 19.57, 29.93, 28.69 and 16.24 degrees in term of 2 theta , (e) X-ray powder diffraction pattern substantially as depicted in figure 1 of the given specification, where the peak at 16.98 degrees in term of 2 theta has a intensity of at least 50% preferably at least 99% with respect to the strongest peak in the X-ray powder diffraction pattern as depicted in figure 1, is new. INDEPENDENT CLAIMS are also included for:    (1) preparing the substantially pure form I of apixaben;    (2) a substantially pure amorphous form of apixaban; and    (3) preparing the substantially pure amorphous form of apixaban comprising dissolving apixaban in alcohol solvent to form a solution and spray drying the solution to form the substantially pure amorphous form of apixaban.